Introduction
The host immune system plays a fundamental role in the elimination as well as the progression and maintenance of cancer. Control (3) (4) (5) (6) (7) (8) (9) (10) (11) . The events that lead to reduced pMHC I may be genetic (mutations and gene deletions) or regulatory (loss or reduction in transcription). These effects can be i) directly on MHC I genes, ii) as a result of defects in peptide generation, targeting immunoproteasomal components LMP2, LMP7 and LMP10 and the endoplasmic reticulum aminopeptidases (ERAP1/2), or iii) in peptide transport or loading of MHC I molecules, involving the transporter associated with antigen processing (TAP), chaperones calnexin (CNX), calreticulin (CRT) and ERp57, and the peptide editor tapasin (Tpn, figure 1 ) (2). These alterations have been most commonly documented in melanoma, cervical, colorectal, gastric, head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), breast, prostate and ovarian cancers (4, 5, 7, (12) (13) (14) (15) (16) (17) . The precise alterations and their consequence are discussed below.
Antigen processing
MHC I molecules present a diverse array of peptides at the cell surface.
These peptides originate from both functional proteins involved in a number of cellular processes and defective ribosomal products (DRiPs) that arise from defective protein synthesis and are rapidly degraded within the cytosol. The peptide binding groove formed within the 1 and 2 domains of MHC I heavy chain (HC) is highly polymorphic in order to accommodate a vast number of peptides. To ensure high affinity binding into the peptide binding groove of MHC I, peptides are typically cleaved to 8-11 amino acids in length and contain specific amino acid properties at anchor residues (position2/5 and Cterminal amino acids). In order to generate optimal peptide antigens, two key processing events exist within the APP pathway. The initial peptide proteolysis occurs within the cytosol of the cell and degrades larger protein fragments into smaller peptides by the proteasome/immunoproteasome (figure 1). This processing event is often responsible for generating the final C-terminal residue of peptides that bind to MHC I. Upon entering the ER, the majority of peptides require further 'fine-tuning' through processing of the Nterminal region by ERAP1/2 prior to its association with MHC I (figure 1).
Whilst these two processing events occur independently, defects in either one or both results in a significant alteration in the ability to produce stable pMHC I complexes that reach the cell surface. In turn, the orchestration of a sufficient immune response, where necessary, becomes impaired and therefore indicates a successful immune escape mechanism for tumour growth.
Proteasome and immunoproteasome
The proteasome, a multicatalytic enzyme residing within the cytosol, is responsible for the turnover of the majority of cellular proteins and has two major roles; i) to regulate cellular protein homeostasis through the ubiquitinproteasome system, preventing the aggregation of misfolded proteins and ii) to generate peptide antigens for MHC I presentation at the cell surface (18) (19) (20) . Three catalytic subunits, β1, β2 and β5, are responsible for the proteolytic activity of the 20S subunit core of the proteasome. However, in non-malignant cells, inflammatory cytokines, such as IFN-, promotes an upregulation of specific catalytic subunits; LMP2, LMP7, and LMP10, incorporated into the 20S proteasome in place of β1, β2 and β5 subunits (21) (22) (23) . These alterations result in the increased generation of antigenic peptides, favouring cleavage after hydrophobic residues, providing the optimal C-terminal anchor residue for stable binding to MHC I. The deletion or reduction of these immunoproteasome subunits significantly impacts the quantity of suitable peptides available, reducing pMHC I expression by up to 50%, and is exploited by a large number of tumours to evade the immune response (24, 25) . If observed at an early stage, immunoproteasome downregulation is associated with an increase in both metastasis and disease recurrence (26) .
Furthermore, single nucleotide polymorphisms (SNPs) in LMP2 and LMP7 are associated with a worse overall survival in cervical carcinoma, most likely as a consequence of altered protein function (17, 27) , These associations suggest that restoring immunoproteasome expression by IFN- would be therapeutically beneficial. Modulation of proteasomal function is being used in the clinic, however, these drugs inhibit proteasome function to prevent destruction of pro-apoptotic proteins and therefore may serve to promote immune evasion in any surviving tumour cells (28).
Endoplasmic reticulum aminopeptidases
Peptides generated in the cytosol are transported through TAP into the ER.
As TAP preferentially transports peptides of 11-14 amino acids, peptides are often too long for stable binding to MHC I and require further processing.
ERAP1 and ERAP2 serve as editors of the peptide repertoire by trimming Nterminal extensions of antigenic peptides, creating a pool of peptides with high affinity for MHC I binding (29) (30) (31) (32) . Interestingly, loss of ERAP1 results in qualitative and quantitative changes in pMHC I reducing expression by up to 50% dependent on the allele (33) (34) (35) . With its role in editing the presented peptide repertoire, tumours target ERAP1 by altering expression at both the transcriptional and post-transcriptional level (36, 37) . Interestingly, the ERAP1 expression is highly variable in tumours being both increased and decreased, however, total loss of expression is not common (37) . Why expression varies so much in tumours is not known, but we have shown that ERAP1 destroys the tAg GSW11 in the murine tumour model CT26 and reducing ERAP1 expression increased GSW11 generation leading to CTL-mediated tumour protection (38) . An increase in ERAP1 expression may therefore allow immune evasion in some tumours through the destruction of antigenic peptides. Consistent with this, increased ERAP1 expression was observed in colorectal adenocarcinoma (39) . By contrast, a loss of ERAP1 expression, associated with a poorer prognosis and overall survival in cervical carcinoma, may restrict the ability to generate tAgs and reduce pMHC I expression (7, 40) .
SNPs in ERAP1 have been associated with poorer prognosis and greater disease progression in HPV+ cervical carcinoma (40) . A combination of SNPs in ERAP1, TAP2 and LMP7 is associated with an increased risk of developing cervical carcinoma (40, 41) . In addition, the presence of a homozygous ERAP1 haplotype (ERAP1-56 major and ERAP-127 minor) correlates with a significantly worse overall survival, highlighting ERAP1 as an independent predictor of survival (40) . The functional consequences of these SNPs are currently unknown, however, other ERAP1 SNPs that exist in multiple combinations as discrete allotypes significantly alter function and, since they are co-dominantly expressed, the combination of allotypes also affects overall function (35, 42) . These differences in ERAP1 function may alter the ability to generate tAgs and reduce anti-tumour CTL responses, suggesting a significant role of ERAP1 in the control of tumours. Furthermore, reduced function may serve to reduce pMHC I expression as observed in cervical carcinoma and head and neck squamous cell carcinoma cases (3, 7) . Therefore modulating ERAP1 activity through inhibitors may provide a unique and novel tool to induce protective anti-tumour CTL responses (43).
Antigen presentation
The presentation of optimal high affinity peptide antigens depends on a sequence of crucial steps involving peptide transport, folding and loading onto 
Chaperones
ER-resident chaperones aid the folding and association of immature HC and 2m before association with the PLC. CRT and CNX are involved in a vast number of cellular processes including APP. Altered expression of CRT and CNX has been linked with a number of tumour types; bladder, prostate, hepatocellular carcinoma, oesophageal, colon, cervical, breast, melanoma and leukaemia, although, most of these associations are due to other cellular functions; cell cycle regulation (down), cell migration and adhesion (up), and ER stress (up) (2, 50, 51) . CRT exposure at the cell surface promotes phagocytosis and engulfment by macrophages, resulting in destruction of tumour cells by immunogenic cell death (52) . Interestingly, like CRT, the additional cellular role of CNX in ER stress has been implicated in cancer, with an increase in CNX expression linked with poor prognosis in colorectal cancer (53) , and shown to be a diagnostic marker in lung cancer (54) . The reduced expression of the thiol oxidoreductase, ERp57, that aids the formation of disulphide bonds to form the PLC, was shown to be an independent predictor of overall survival in cervical carcinoma (55) and both the reduction and loss of ERp57 are correlated with progression of gastric cancer (56).
Tapasin
Tpn serves as a bridge between MHC I, TAP and CRT and is essential for ERp57 association to form a stable PLC. Tpn, as part of the PLC, has a unique role in peptide editing of MHC I bound peptides, by facilitating the release of sub-optimal fast off-rate peptides to enable optimal slow-off rate peptides to bind and form a stable pMHC I molecule (57) . This quality control feature of Tpn is essential and influences the peptide repertoire; more stable peptides with a longer half-life are favoured for presentation (58) . As such, Tpn deficiency has severe effects on most MHC I alleles, resulting in fewer stable pMHC I expressed at the cell surface (57, 59) Heterogenous expression of Tpn levels, but an overall downregulation, is observed in comparison to normal controls in RCC, colon carcinoma, small cell lung carcinoma, HNSCC, and pancreatic carcinoma cells (2) . Levels of Tpn directly correlate with pMHC I expression, suggesting Tpn may contribute to the immune escape phenotype of these tumours (60) . More recently, a reduction in Tpn (down-regulated in 48% cases) was correlated not only with prognosis but also levels of CTL responses in colorectal carcinoma; high levels Tpn expression correlated with high CD8+ infiltrate, independent of pMHC I levels (61) . The association of loss of Tpn function with clinical progression of disease is observed in melanoma, with advanced stages correlating with a significant downregulation (62) . Interestingly, restoring Tpn in murine lung carcinoma (CMT.64) restored MHC and increased the CD8+, CD4+ and CD11C+ infiltrate to the tumour site (63) . In addition, when both Tpn and TAP function were restored, a significantly greater protective response was generated, suggesting that multiple aspects of the APP pathway need to function in order to generate a maximal response (63) .
Expression of Tpn is not always associated with a positive outcome as increased Tpn expression in the murine pancreatic tumour cell line, Panc02, reduced the presentation of an immunodominant tAg resulting in lack of immune recognition (64) . Therefore, the activity of Tpn in tumours is able to carefully modulate both the quality and quantity of tAgs displayed by MHC I.
There is a vast array of evidence that demonstrates alterations within the APP pathway among most tumour types. These encompass almost all the components of the APP and whilst inducing down regulation of MHC I they also alter the repertoire of antigenic peptides presented to CTL. Interestingly, IFN- stimulation is able to restore expression of APM in cancer cell lines, suggesting that targeting these components and modulating their expression may provide immunotherapeutic strategies to increase the visibility of cancerous cells and allow recruitment of specialised immune cells to target and eliminate cancer (65).
MHC II antigen processing and presentation in tumour immune escape
In normal cellular environments, classical major histocompatibility complex 
Tumour microenvironment
The TME is a complex and dynamic interaction between tumour cells and (87) . Although the tAg presenting capacity of both TAM phenotypes was lower than conventional DCs, the TAM-MHC II LOW correlates with poorer APP capacity than TAM-MHC II HIGH and are able to supress T cell activation (87) . Whilst the effect of this altered M1 to M2 phenotype on APM components has not been studied, it is likely that components of both the MHC I and MHC II APP pathways are also downregulated in response to pro-tumourigenic activity, limiting the supply of peptides that are required for MHC presentation.
Conclusions
In this review we have discussed the regulation of the APP pathway in the 
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